Ibrahim El-Deeb has a PhD degree in Biomolecular Sciences from the University of Science and Technology (UST) in South Korea (earned in 2010). Ibrahimís PhD degree was fully funded through a scholarship awarded from Korea Institute for Science and Technology (KIST). In late 2010, Ibrahim joined Prof. Mark von Itzsteinís group in the Institute for Glycomics at Griffith University, as a research fellow. In 2012, Ibrahim was awarded a Griffith University Postdoctoral and Research Fellowship (GUPRF) for a period of three years to continue his research projects within the von Itzstein group. In late 2016, Ibrahim moved to the royal college of surgeons in Ireland (Bahraincampus) to start an assistant professor position in the school of Medicine.To date Ibrahim published 26 peer-reviewed articles in peer-reviewed journals. He has also contributed to four drug discovery patents targeting treatment of cancer and parainfluenza virus infection. Ibrahim has presented his research output in several national and international conferences, and was an invited speaker in a number of them, such as Pacifichem 2015 in Hawaii (The biggest chemistry research conference in the pacific region) and Sialoglyco 2014 on the Gold Coast.
Ibrahimís research interests encompass different areas of Chemical Biology and Drug Discovery. The two main areas he has been actively engaged in during the last 10 years are the antiviral research (mainly against parainfluenza virus), and anticancer research. Ibrahimís research group in Griffith University succeeded to discover the most potent anti-parainfluenza virus candidate to date that is currently undergoing preclinical trials. In the space of anticancer research, Ibrahim worked extensively on kinase inhibitors as novel and more selective agents for treatment of cancer, and on the highly potent anticancer Duocarmycin derivatives.